2026 Global: Anticoagulant Reversal-Competitive Review (2032) report
Description
The 2026 Global: Anticoagulant Reversal-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for anticoagulant reversal by geography and historical trend. The scope of the report extends to sizing of the anticoagulant reversal market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Pfizer Inc., AstraZeneca, Boehringer Ingelheim International GmbH, CSL Behring LLC, and Octapharma AG lead the anticoagulant reversal drugs market, commanding significant shares through innovative products like idarucizumab and prothrombin complex concentrates (PCCs). Pfizer holds approximately 16.3% market share, leveraging strategic hospital partnerships and distribution excellence for reversal agents targeting direct oral anticoagulants (DOACs). AstraZeneca's Praxbind (idarucizumab) dominates with 36.8% revenue in 2024, offering rapid reversal of dabigatran in emergencies, bolstered by clinical efficacy and regulatory approvals. Boehringer Ingelheim pioneers targeted therapies, establishing benchmarks for thrombin inhibitor reversal and maintaining influence via pipeline innovation. CSL Behring excels in plasma-derived PCCs, providing reliable hemostasis in trauma and surgical settings with robust global manufacturing. Octapharma AG advances protein-based agents, emphasizing safety, scalability, and recent launches like Balfaxar for vitamin K antagonist reversal.
Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Endo International plc, and Sun Pharmaceutical Industries Ltd. compete as key challengers, focusing on generics and regional expansion in this moderately concentrated market. Teva and Endo maintain strong portfolios for DOAC and warfarin reversal, capitalizing on cost-effective formulations amid rising atrial fibrillation cases. Dr. Reddy's Laboratories supports market growth through accessible generics, aligning with demand in emerging economies like India and China. Sun Pharmaceutical enhances accessibility via diverse channels, contributing to the projected CAGR of segments like andexanet alfa at 21.9%. These firms navigate regulatory hurdles and bleeding risks, driving affordability while top players control 45-55% share.
Novartis AG, Bausch Health Companies Inc., and Portola Pharmaceuticals round out the top ten, innovating amid trends toward Factor Xa inhibitors and monoclonal antibodies. Novartis bolsters its position via acquisitions like Anthos Therapeutics, targeting reduced bleeding reversal needs. Bausch Health provides versatile options like PCCs and vitamin K, prominent in North America’s dominant market. Portola advances specific agents like andexanet alfa, addressing high-cost DOAC reversal despite challenges. Collectively, these companies fuel growth from USD 1.6 billion in 2025 to USD 4.0 billion by 2035, propelled by coagulation disorders and emergency care demands.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for anticoagulant reversal by geography and historical trend. The scope of the report extends to sizing of the anticoagulant reversal market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Pfizer Inc., AstraZeneca, Boehringer Ingelheim International GmbH, CSL Behring LLC, and Octapharma AG lead the anticoagulant reversal drugs market, commanding significant shares through innovative products like idarucizumab and prothrombin complex concentrates (PCCs). Pfizer holds approximately 16.3% market share, leveraging strategic hospital partnerships and distribution excellence for reversal agents targeting direct oral anticoagulants (DOACs). AstraZeneca's Praxbind (idarucizumab) dominates with 36.8% revenue in 2024, offering rapid reversal of dabigatran in emergencies, bolstered by clinical efficacy and regulatory approvals. Boehringer Ingelheim pioneers targeted therapies, establishing benchmarks for thrombin inhibitor reversal and maintaining influence via pipeline innovation. CSL Behring excels in plasma-derived PCCs, providing reliable hemostasis in trauma and surgical settings with robust global manufacturing. Octapharma AG advances protein-based agents, emphasizing safety, scalability, and recent launches like Balfaxar for vitamin K antagonist reversal.
Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Endo International plc, and Sun Pharmaceutical Industries Ltd. compete as key challengers, focusing on generics and regional expansion in this moderately concentrated market. Teva and Endo maintain strong portfolios for DOAC and warfarin reversal, capitalizing on cost-effective formulations amid rising atrial fibrillation cases. Dr. Reddy's Laboratories supports market growth through accessible generics, aligning with demand in emerging economies like India and China. Sun Pharmaceutical enhances accessibility via diverse channels, contributing to the projected CAGR of segments like andexanet alfa at 21.9%. These firms navigate regulatory hurdles and bleeding risks, driving affordability while top players control 45-55% share.
Novartis AG, Bausch Health Companies Inc., and Portola Pharmaceuticals round out the top ten, innovating amid trends toward Factor Xa inhibitors and monoclonal antibodies. Novartis bolsters its position via acquisitions like Anthos Therapeutics, targeting reduced bleeding reversal needs. Bausch Health provides versatile options like PCCs and vitamin K, prominent in North America’s dominant market. Portola advances specific agents like andexanet alfa, addressing high-cost DOAC reversal despite challenges. Collectively, these companies fuel growth from USD 1.6 billion in 2025 to USD 4.0 billion by 2035, propelled by coagulation disorders and emergency care demands.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
